FDA
-
-
-
-
-
-
-
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
-
-
-
-
-
-
-
ESSA Pharma (EPIX) Suspends Enrollment in Phase 1 Study of EPI-7386
-
-
-
-
-
-
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022
-
-
-
-
-
-
-
Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration
-
-
-
-
-
-
-
ESSA Pharma Inc. (EPIX) Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
-
-
-
-
-
-
-
ESSA Pharma to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
ESSA Pharma Inc. (EPIX) Prices 7.1M Share Common Offering at $6/Sh
-
322,096 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

